Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Next Previous
X
Search
Trial Profile

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms Averectal study

    • Most Recent Events

    • 30 Jan 2024 Planned End Date changed from 2 Jun 2024 to 2 Jul 2024.
    • 01 Jul 2023 Results assessing evaluate the NAR scores correlation with PFS and OS in patients enrolled in the Averectal study presented at the 25th World Congress on Gastrointestinal Cancer
    • 21 Jan 2023 Results of QOL data from the Averectal study, which assessed the efficacy and safety of neoadjuvant short course radiotherapy plus chemo-immunotherapy for patients with LARC, presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top